Initiation of an investigator-sponsored trial by Imperial College London to evaluate the efficacy of fostamatinib for the treatment of COVID-19 pneumonia. Rigel Pharma
Rigel Pharmaceuticals, Inc. announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase… read more.